Early translational work gets the credit for Sage Therapeutics Inc.'s set of late-stage trial readouts due near term, CEO Jeff Jonas told BioWorld. "If you look back at biotech companies in general, I'm not sure I can think of another company that's had such a wealth of potential inflection points clustered together within six months, and having achieved that in such a short period of time," he said.